Johnson Controls International plc JCI has been witnessing strong momentum in the Building Solutions North America segment, ...

NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Analysts on Wall Street project that Johnson & Johnson (JNJ) will announce quarterly earnings of $2 per share in its forthcoming report, representing a decline of 12.7% year over year. Revenues are ...

The Dogs of the Dow strategy doesn’t always work. Often, it can lead investors to a laggard poised to lag behind for yet ...

The Bears' ability to sign Ben Johnson became a real point of debate on Wednesday but the Lions offensive coordinator did seek to clear up one budding concern.

This fall, pharmaceutical and medical technology company Johnson & Johnson announced that a newly created Dallas subsidiary ...

These companies headline a $1.4 trillion industry, have staying power, and will pay you well to hold their stock.

BioSpace recaps 2024’s top venture capital rounds in biopharma, from Xaira Therapeutics’ blockbuster $1B raise to ...

S&P Global Ratings placed Johnson & Johnson on CreditWatch with negative implications, citing its nearly $15 billion deal to acquire mental-illness drug developer Intra-Cellular Therapies.

Johnson & Johnson's $14.6bn acquisition of Intra-Cellular Therapies adds Caplyta and a robust pipeline targeting major ...

Intra-Cellular Therapies stock leapt more than 30% Monday morning, after Johnson & Johnson agreed to buy the ...